Those undergoing cancer treatment find themselves facing the fight of their lives.
And many health experts are eager to discover an effective cancer treatment method that isn’t as devastating as radiation and chemo.
Perhaps one of the most known is vitamin B17.
Sloan-Kettering’s cancer research facility in New York.
Ralph Moss joined the center in 1974, just as they were testing Laetrile – a form of vitamin B17.
It was Moss’ first big job, and he was right in the midst of a potentially earth-shattering discovery.
But the tides quickly changed as Sloan-Kettering’s Board of Directors learned more. Laetrile was swept under the rug, and the research put aside when Laetrile was determined to be potentially harmful.
Ralph Moss couldn’t sit on what he saw as B17’s potential. He called a press conference on his own and accused his employer of orchestrating a major coverup of B17 research.
Laetrile has since been banned in the United States.
Why The Ban?
“I have found no statements of demonstrated pharmacological harmfulness of amygdalin to human beings at any dosages recommended or employed by medical doctors in the United States and abroad.”
The Research Continues
Even though vitamin B17 has been banned and condemned as toxic in the U.S., researchers from around the world have continued to find positive results in clinical studies.
In 2003, researchers found amygdalin from peach pits to have an influence on tumor growth.
In 2006, it was found to induce apoptosis by regulating Bax and Bcl-2 expressions in cancer cells.
In 2013, it was found to be a potentially effective means of treating cervical cancer.
In 2014, researchers found it to influence bladder cancer tumors.
What You Can Do
Ralph Moss – that former employee of Sloan-Kettering – has put together a petition urging his former employer to acknowledge its positive results. You can sign that petition here.